Zobrazeno 1 - 10 of 283 pro vyhledávání: '"Tarzi, R."'
2
Akademický článek
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
Autor: D'Haens G; Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Peyrin-Biroulet L; Inserm NGERE and Department of Gastroenterology, University Hospital of Nancy, Université de Lorraine, Vandoeuvre-les-Nancy, France., Marks DJB; GSK, Discovery Medicine, GSK Medicine Research Centre, Stevenage, UK., Lisi E; GSK, Biostatistics, GSK Medicines Research Centre, Stevenage, UK., Liefaard L; GSK, Clinical Pharmacology Modelling and Simulation, GSK Medicines Research Centre, Stevenage, UK., Beaton A; GSK, Clinical Sciences, Medicines Research Centre, London, UK., Srinivasan N; GSK, Immunology Research Unit, Stevenage, UK., Bouma G; GSK, Clinical Pharmacology and Experimental Medicine, GSK Medicines Research Centre, Stevenage, UK., Prasad N; GSK, Computational Biology, Genomic Sciences Group, Stevenage, UK., Cameron R; GSK, Clinical Sciences, GSK, London, UK., Kayali Z; ACE Endoscopy, Suite C Inland Empire Liver Foundation, Rialto, California, USA., Tarzi R; GSK, Clinical Sciences, Medicines Research Centre, Stevenage, UK., Hanauer S; Northwestern University Feinberg School of Medicine, Northwestern Medicine Digestive Health Center, Chicago, Illinois, USA., Sandborn WJ; Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Aug; Vol. 58 (3), pp. 283-296. Date of Electronic Publication: 2023 Jun 16.
Zobrazit plný text záznamu
3
RIPK3-deficient mice were not protected from nephrotoxic nephritis
Autor: Hill, NR, Cook, T, Pusey, C, Tarzi, R
Publikováno v: BMC Nephrology, Vol 19, Iss 1, Pp 1-8 (2018)
Background/Aims: Necrotizing glomerular lesions are a feature of severe glomerulonephritis. Unlike apoptosis, cellular necrosis has the potential to release damage-associated proteins into the microenvironment, thereby potentiating inflammation. Unti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b4bca747149569fef9c8bb5d575cb83e
http://link.springer.com/article/10.1186/s12882-018-0850-4
Zobrazit plný text záznamu
4
Akademický článek
Randomized Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2831781 in Healthy Japanese and White Participants.
Autor: Liefaard L; Clinical Pharmacology Modelling and Simulation, GSK, Stevenage, UK., Hajduk E; Global Clinical Sciences and Delivery, GSK, Brentford, UK., van den Berg F; Hammersmith Medicines Research, London, UK., Panoilia E; Clinical Pharmacology Modelling and Simulation, GSK, Stevenage, UK., Bouma G; Clinical Pharmacology and Experimental Medicine, GSK, Stevenage, UK., Lisi E; Biostatistics, GSK, Stevenage, UK., Srinivasan N; Adaptive Immunity Research Unit, GSK, Stevenage, UK., Cui Y; Global Safety, GSK, Brentford, UK., Gross AS; Clinical Pharmacology Modelling and Simulation, GSK, Sydney, Australia., Tarzi R; Clinical Science, GSK, Stevenage, UK., Marks DJB; Clinical Pharmacology and Experimental Medicine, GSK, Stevenage, UK.
Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Nov; Vol. 11 (11), pp. 1284-1293. Date of Electronic Publication: 2022 Sep 11.
Zobrazit plný text záznamu
7
Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy
Autor: Turner-Stokes, T, Wilson, HR, Morreale, M, Nunes, A, Cairns, T, Cook, HT, Pusey, C, Tarzi, R, Lightstone, L
Class IV-S lupus nephritis (LN) is often associated with more necrosis and fewer subendothelial immune deposits compared to class IV-G LN, suggestive of the necrotising glomerular inflammation found in ANCA-associated vasculitis. ANCA are present in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::ffb56839661a7e71b8d5fc60f2f1c8d9
http://hdl.handle.net/10044/1/53672
Zobrazit plný text záznamu
8
Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series
Autor: McAdoo, SP, Bedi, R, Tarzi, R, Griffith, M, Pusey, CD, Cairns, T
B cell depletion is an effective treatment strategy in ANCA-associated vasculitis (AAV). Ofatumumab is a fully humanized anti-CD20 mAb that has shown efficacy in the treatment of haematological malignancy and RA. The use of ofatumumab in the treatmen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::178ba996c29f4a11289e534cb360d11c
http://hdl.handle.net/10044/1/30419
Zobrazit plný text záznamu
9
Akademický článek
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome.
Autor: Jimenez-Royo P; Research and Development, GlaxoSmithKline, Stevenage., Bombardieri M; Experimental Medicine and Rheumatology, Queen Mary University of London, London., Ciurtin C; Centre for Adolescent Rheumatology, University College London, London., Kostapanos M; GlaxoSmithKline Clinical Unit Cambridge, Cambridge.; Department of Medicine, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge., Tappuni AR; Institute of Dentistry, Queen Mary University of London, London., Jordan N; Rheumatology Department, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge., Saleem A; Invicro, Centre for Imaging Sciences, A Konica Minolta Company, London.; Faculty of Health Sciences, University of Hull, Hull., Fuller T; Research and Development, GlaxoSmithKline, Stevenage., Port K; Research and Development, GlaxoSmithKline, Stevenage., Pontarini E; Experimental Medicine and Rheumatology, Queen Mary University of London, London., Lucchesi D; Experimental Medicine and Rheumatology, Queen Mary University of London, London., Janiczek R; Research and Development, GlaxoSmithKline, Stevenage., Galette P; Research and Development, GlaxoSmithKline, Stevenage., Searle G; Invicro, Centre for Imaging Sciences, A Konica Minolta Company, London., Patel N; Research and Development, GlaxoSmithKline, Stevenage., Kershaw L; Centre for Inflammation Research, University of Edinburgh.; Edinburgh Imaging, University of Edinburgh, Edinburgh., Gray C; Edinburgh Imaging, University of Edinburgh, Edinburgh., Ratia N; Research and Development, GlaxoSmithKline, Stevenage., van Maurik A; Research and Development, GlaxoSmithKline, Stevenage., de Groot M; Research and Development, GlaxoSmithKline, Stevenage.; GlaxoSmithKline Clinical Unit Cambridge, Cambridge., Wisniacki N; Research and Development, GlaxoSmithKline, Stevenage., Bergstrom M; Research and Development, GlaxoSmithKline, Stevenage., Tarzi R; Research and Development, GlaxoSmithKline, Stevenage.
Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2021 May 14; Vol. 60 (5), pp. 2396-2408.
Zobrazit plný text záznamu
10
Akademický článek
Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis.
Autor: Slevin SM; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Garner LC; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Lahiff C; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Tan M; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Wang LM; Department of Laboratory Medicine, Changi General Hospital, SingHealth, Singapore., Ferry H; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Greenaway B; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Lynch K; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Geremia A; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Hughes S; Experimental Medicine Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, UK., Leavens K; Experimental Medicine Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, UK., Krull D; GlaxoSmithKline, Collegeville, Pennsylvania, USA., Marks DJB; Experimental Medicine Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, UK., Nevin K; Experimental Medicine Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, UK., Page K; Experimental Medicine Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, UK., Srinivasan N; Experimental Medicine Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, UK., Tarzi R; Experimental Medicine Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, UK., Klenerman P; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK.; The Peter Medawar Building for Pathogen Research, University of Oxford, UK., Travis S; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Arancibia-Cárcamo CV; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK., Keshav S; NIHR Oxford Biomedical Research Centre, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, Nuffield Department of Experimental Medicine, John Radcliffe Hospital, University of Oxford, UK.
Publikováno v: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Oct 05; Vol. 14 (10), pp. 1446-1461.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje